Fundamentals of HIV Medicine 2017Oxford University Press, 15 maj 2017 - 616 Completely updated for 2017, Fundamentals of HIV Medicine is a comprehensive clinical care publication for the treatment of HIV/AIDS. Published by the American Academy of HIV Medicine, the book offers physicians, pharmacists, nurse practitioners, and other care providers the most up-to-date overview of the latest HIV treatments and guidelines. Embodying the AAHIVM's commitment to promoting uniform excellence in care of seropositive patients, Fundamentals of HIV Medicine 2017 empowers health professionals to deliver standardized, life-sustaining treatment to the patients who need it most. It will serve as an essential clinical reference and provide valuable career enrichment to users across the spectrum of HIV care, treatment, and prevention. |
Spis treści
| 1 | |
2 The Origin Evolution and Epidemiology of HIV1 and HIV2 | 17 |
3 Mechanisms of HIV Transmission | 23 |
4 HIV Transmission Prevention | 27 |
5 Immunology | 51 |
6 HIV Cure Strategies | 63 |
7 HIV Testing and Counseling | 69 |
Detection and Diagnosis | 75 |
28 Immunosuppressants and Antiretroviral Therapy in HIVPositive Transplant Patients | 305 |
29 Understanding and Managing Antineoplastic and Antiretroviral Therapy | 309 |
30 Substance Abuse in HIV Populations | 319 |
31 Understanding the Use of Antiretroviral Drugs in the Aging Patient | 329 |
32 Opportunistic Infections | 335 |
33 Malignant Diseases in HIV | 351 |
34 Dermatologic Complications | 389 |
35 Endocrine Disorders | 403 |
9 The Medical History and Physical Examination of the HIVInfected Patient | 87 |
10 Initial Laboratory Evaluation and Risk Stratification of the HIVInfected Patient | 91 |
11 Clinical Syndromes and Differential Diagnosis in the HIVInfected Patient | 95 |
12 Health Maintenance | 101 |
13 Issues in Specific Patient Populations | 121 |
14 Complementary and Alternative MedicineIntegrative Medicine Approaches | 171 |
15 Care Coordination | 187 |
16 Palliative Care and EndofLife Support | 199 |
17 HIV Virology | 207 |
18 Principles of Applied Clinical Pharmacokinetics and Pharmacodynamics in Antiretroviral Therapy | 219 |
19 Classes of Antiretrovirals | 227 |
What to Start With | 241 |
21 HIV1 Resistance to Antiretroviral Drugs | 249 |
22 Managing the Patient with MultidrugResistant HIV | 263 |
23 Future Antiretrovirals ImmuneBased Strategies and Therapeutic Vaccines | 267 |
24 The Pharmacists Role in Caring for HIVPositive Individuals | 279 |
25 Solid Organ Transplantation in HIVInfected Individuals | 285 |
26 Antiretroviral Therapy in Pregnant Women | 291 |
27 Antiretroviral Therapy in Children and Newborns | 297 |
Respiratory Complications | 411 |
37 Psychiatric Illness and Treatment in HIV Populations | 415 |
38 HIVAssociated Neurocognitive Disorders | 427 |
39 HIVHepatitis Coinfection | 447 |
40 Ocular Complications | 467 |
41 Cardiovascular Disease | 475 |
42 Renal Complications | 487 |
43 Musculoskeletal Complications of HIV | 499 |
44 Sexually Transmitted Diseases | 505 |
45 HIV and Bone Health | 513 |
46 HIVAssociated Lipodystrophy and Lipoatrophy | 523 |
47 Dyslipidemia | 529 |
48 Immune Reconstitution Inflammatory Syndrome | 537 |
49 US Health Care Systems HIV Programs and Coverage Policy Issues | 543 |
50 Legal Issues | 549 |
51 Research Design and Analysis | 565 |
52 Ethical Conduct of Clinical Trials Institutional Review Boards Informed Consent and Financial Conflicts of Interest | 569 |
| 573 | |
Inne wydania - Wyświetl wszystko
Kluczowe wyrazy i wyrażenia
abacavir acute adults agents AIDS antibody antiretroviral drugs antiretroviral therapy assays associated atazanavir Available cancer CD4+ cell counts CD4+ T cell cells/mm3 Centers for Disease chronic Clin Infect clinical trials co-infected cohort Control and Prevention darunavir decrease diagnosis dose drug efavirenz effects efficacy emtricitabine guidelines HAART hepatitis HIV patients HIV testing HIV transmission HIV-associated HIV-infected individuals HIV-infected patients HIV-positive HIV/AIDS human immunodeficiency virus Immune Defic Syndr incidence increased risk initiation integrase integrase inhibitor interactions LEARNING OBJECTIVE lesions levels liver lymphoma metabolism mutations NNRTIs NRTIs opportunistic infections patients with HIV pharmacokinetic plasma population prevalence programs prophylaxis protease inhibitors raltegravir randomized rates recommended reduce regimen renal resistance retinitis reverse transcriptase reverse transcriptase inhibitors rilpivirine risk factors ritonavir screening sexual symptoms syndrome tenofovir tion toxicity transgender transplant treatment vaccine viral load virologic WHAT’S women zidovudine